Sera Prognostics

Sera Prognostics, Inc. engages in the provision of personalized diagnostics to predict and manage pregnancy complications. It focuses on developing blood tests to predict the risks of preterm birth, preeclampsia and other pregnancy complications. The company was founded by Steven W. Graves, Dennis Farrar and M. Sean Esplin in 2008 and is headquartered in Salt Lake City, UT.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Sera Prognostics reports revenue growth and innovation drive amidst challenges

Sera Prognostics demonstrated strong financial performance with revenue growth and reduced net loss in Q4 2022.
The company's focus on innovation, new data, and upcoming studies positions it well for future growth and market success.
Challenges in revenue expectations and payer dynamics require strategic navigation, but opportunities from studies and technology advancements are promising.

Sera Prognostics reports robust Q1 performance amidst revenue challenges

Sera Prognostics demonstrated strong performance in Q1 2023 with notable revenue growth and positive trial outcomes, showcasing its research capabilities and commitment to innovation.
While facing challenges in revenue projections and financial losses, the company's strategic focus on cost efficiency and strong cash reserves provide a foundation for future growth.
Opportunities lie in upcoming study analyses, continued research efforts, and potential partnerships, positioning Sera Prognostics for sustainable development and market expansion.

Sera Prognostics reports stable Q2 revenue, eyes growth opportunities

Sera Prognostics demonstrated stable financial performance in Q2 2023, with a focus on revenue growth and cost management.
The company's PreTRM test showed promising results in reducing neonatal length of stay, enhancing its market position.
While facing challenges in commercialization and global scaling, Sera has opportunities to expand revenue streams and strengthen partnerships.

SERA reports Q3 revenue growth, focuses on expense management

SERA's financials show revenue growth potential with a focus on expense management
Balancing product development and study outcomes crucial for future success
Strategic steps taken to ensure operational sustainability and revenue growth

Sera Prognostics reports positive study outcomes amidst financial challenges

Sera Prognostics demonstrated positive study outcomes with potential for improved neonatal health, despite a net loss in Q4 2023.
Strategic focus on managing expenses, leveraging study results, and achieving key milestones for future revenue growth.
Opportunities lie in lower cash expenses for 2024, revenue growth initiatives, and the launch of a blood sample self-collection device.
Challenges include balancing financial performance, cash management, and addressing analyst inquiries.

Sera Prognostics reports improved Q1 financials and eyes global expansion

Sera Prognostics made strides in financial performance and operational efficiency in Q1 2024.
The company's focus on expanding test adoption and improving margins shows promise for growth.
Despite challenges like regulatory impacts, Sera Prognostics is poised for strategic investments and market expansion.

Sera Prognostics reports Q2 revenue decline, focuses on growth strategies

Sera Prognostics navigated challenges with decreased revenue and a net loss in Q2 2024, emphasizing cost management and efficiency.
The company's strengths lie in strategic progress, enhanced market visibility, and new market opportunities with the PreTRM Test approval.
Opportunities exist in leveraging study results for product adoption, expanding market reach through awareness initiatives, and utilizing financial flexibility for growth.

Sera Prognostics focuses on combating premature births, strengthens revenue growth

Sera Prognostics is actively working to combat premature birth risks in the U.S.
Despite financial challenges, the company maintains a solid cash position for growth
Strategic initiatives aim to increase revenue and awareness for sustainable progress

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Does Sera Prognostics, Inc. (SERA) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here's Why Sera Prognostics, Inc. (SERA) is a Great Momentum Stock to Buy

Amid another soft session on Wall Street, Sera Prognostics (NASDAQ: SERA ) — a specialist in the field of maternal and neonatal health — shook up the market with a dramatic increase in value. Fueling the blistering ride was encouraging data for its clinical study regarding risk assessment of premature delivery.

Why Is Sera Prognostics (SERA) Stock Up 260% Today?

SALT LAKE CITY , Dec. 6, 2023 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the Data Safety Monitoring Board (DSMB) overseeing its pivotal Prematurity Risk Assessment Combined with Clinical Interventions for Improved Neonatal OutcoMEs (PRIME) study recommended stopping enrollment due to efficacy, reporting that either of the co-primary endpoints met the stopping criteria for statistical significance at the pre-planned interim analysis. The Company has adopted the DSMB's recommendation and will stop PRIME study enrollment to focus on analyzing and reporting the available data.

SERA PROGNOSTICS ANNOUNCES PRIMARY ENDPOINT CRITERIA MET IN PIVOTAL PRIME STUDY INTERIM LOOK - ENROLLMENT TO STOP DUE TO SUCCESS

SALT LAKE CITY , Nov. 22, 2023 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the upcoming 35th Annual Piper Sandler Healthcare Conference to be held November 28-30, 2023 in New York City. Doug Fisher, Sera's Chief Business Officer, is scheduled to participate in a presentation on November 28, 2023, at 10:50 a.m.

SERA PROGNOSTICS TO PRESENT AT 35TH ANNUAL PIPER SANDLER HEALTHCARE CONFERENCE

Sera Prognostics, Inc (NASDAQ:SERA ) Q3 2023 Earnings Conference Call November 8, 2023 5:00 PM ET Company Participants Peter DeNardo - Investor Relations Zhenya Lindgardt - President and Chief Executive Officer Austin Aerts - Chief Financial Officer Conference Call Participants Maggie Boeye - William Blair Tom Stevens - TD Cowen Operator Good afternoon, and welcome to the Sera Prognostics Conference Call to review Third Quarter Fiscal Year 2023 results. [Operator Instructions] As a reminder, this call is being recorded for replay purposes.

Sera Prognostics, Inc (SERA) Q3 2023 Earnings Call Transcript

SALT LAKE CITY , Nov. 8, 2023 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the third quarter of 2023 ended September 30, 2023. Recent Highlights: Sera Board of Directors approved permanent President and CEO and CFO appointments for Zhenya Lindgardt and Austin Aerts, respectively.

SERA PROGNOSTICS REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS

SALT LAKE CITY , Oct. 25, 2023 /PRNewswire/ -- Sera Prognostics  Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report third quarter fiscal year 2023 financial results on Wednesday, November 8, 2023, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m.

Sera Prognostics Announces Conference Call and Webcast of Third Quarter Fiscal Year 2023 Financial Results on November 8, 2023

AMC Entertainment

Inter Parfums

TripAdvisor

YUM! Brands

Tap five stocks with increasing P/E ratios to try an out-of-the-box approach. These stocks include AMC Entertainment (AMC), Yum Brands (YUM), Inter Parfums (IPAR), TripAdvisor (TRIP) and Sera Prognostics (SERA).

Why You Should Bet on These 5 Top-Ranked Stocks With Rising P/E

Owens-Illinois

Scholar Rock Holding Corp

Valens Semiconductor Ltd

Tap four stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include AMC Entertainment (AMC), Scholar Rock (SRRK), PTK Acquisition (VLN), OI Glass (OI) and Sera Prognostics (SERA).

Why You Should Bet on 4 Top-Ranked Stocks With Rising P/E

SALT LAKE CITY , Sept. 21, 2023 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the upcoming Cantor Fitzgerald Global Healthcare Conference 2023 to be held September 26-28, 2023 in New York City.

SERA PROGNOSTICS TO PRESENT AT CANTOR FITZGERALD GLOBAL HEALTHCARE CONFERENCE 2023

Sera Prognostics, Inc. (SERA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Sera Prognostics, Inc. (SERA) Loses -32.38% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The heavy selling pressure might have exhausted for Sera Prognostics, Inc. (SERA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Sera Prognostics, Inc. (SERA) Loses -38.49% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Sera Prognostics, Inc. (NASDAQ:SERA ) Q2 2023 Earnings Conference Call August 9, 2023 5:00 PM ET Company Participants Peter DeNardo – Investor Relations-CapComm Partners Zhenya Lindgardt – Interim President and Chief Executive Officer Austin Aerts – Interim Chief Financial Officer Conference Call Participants Dustin Scaringe – Blair Operator Good afternoon. And welcome to the Sera Prognostics' conference call to review Second Quarter Fiscal Year 2023 Results.

Sera Prognostics, Inc. (SERA) Q2 2023 Earnings Call Transcript

Sera Prognostics, Inc. (SERA) came out with a quarterly loss of $0.34 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.37 per share a year ago.

Sera Prognostics, Inc. (SERA) Reports Q2 Loss, Tops Revenue Estimates

SALT LAKE CITY , Aug. 9, 2023 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the second quarter of 2023 ended June 30, 2023. Recent Highlights: Announced leadership changes and commercial actions in May 2023 to optimize business for market success toward accelerating test adoption and revenue including aligning management team for new refined commercial focus on institutions.

SERA PROGNOSTICS REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS

SALT LAKE CITY , July 31, 2023 /PRNewswire/ --  Sera Prognostics  Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report second quarter fiscal year 2023 financial results on Wednesday, August 9, 2023, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m.

Sera Prognostics Announces Conference Call and Webcast of Second Quarter Fiscal Year 2023 Financial Results on August 9, 2023

Sera Prognostics is a promising company with a mission to improve pregnancy outcomes through its blood test product, PreTRM, which identifies biomarkers linked to premature birth. Premature birth is a significant issue, with 1 in 10 babies born prematurely in 2021, and it is the leading cause of death in newborns at 34%. The company's strong balance sheet, low price/book value, and global total addressable market make it a strong buy for investors, in my opinion.

Sera Prognostics: Buy The PreTRM Moat

Aligning Management Team given New Refined Commercial Focus on Institutions Starting with Recent Appointment of Board Member Zhenya Lindgardt as Interim President and CEO Engages Leading Strategy House to Evaluate Best Pathways Toward Targeting Enhanced Revenue Generation at Significantly Reduced Operating Costs Nadia Altomare Expected to Move from Chief Commercial Officer to Consulting Role to Support Driving Efficiency and Effectiveness in Our Commercial Spend in Partnership with Our External and Internal Team SALT LAKE CITY , May 25, 2023 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced certain commercial changes and plans to optimize its strategy and commercial structure to highly focus business activities on accelerating test adoption and revenue at significantly reduced operating costs. These plans include changes to better align leadership with a new refined commercial focus on institutions and cost-effectively accelerating test adoption and revenue in advance of upcoming data readouts.

Sera Prognostics Announces Commercial Changes and Actions to Optimize Business for Market Success Toward Accelerating Test Adoption and Revenue

SALT LAKE CITY , May 15, 2023 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the retirement of the Company's President and CEO, Gregory C. Critchfield, M.D.

Sera Prognostics Announces Retirement of President and CEO Dr. Greg Critchfield and Appointment of Board Member Zhenya Lindgardt as Interim CEO

Sera Prognostics, Inc. (NASDAQ:SERA ) Q1 2023 Earnings Conference Call May 10, 2023 5:00 PM ET Company Participants Peter DeNardo - CapComm Partners, IR Greg Critchfield - Chairman, President & Chief Executive Officer Jay Moyes - Chief Financial Officer Conference Call Participants Tom Stevens - Cowen Dan Brennan - Cowen Andrew Brackmann - William Blair Operator Good afternoon, and welcome to the Sera Prognostics Conference Call to review the First Quarter Fiscal Year 2023 results. At this time, all participants are in listen-only mode.

Sera Prognostics, Inc. (SERA) Q1 2023 Earnings Call Transcript

Sera Prognostics, Inc. (SERA) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.40 per share a year ago.

Sera Prognostics, Inc. (SERA) Reports Q1 Loss

SALT LAKE CITY , May 10, 2023 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the first quarter of 2023 ended March 31, 2023. Recent Highlights: Announced positive top-line results from the AVERT PRETERM TRIAL (Serum Assessment of Preterm Birth Outcomes Compared to Historical Controls).

SERA PROGNOSTICS REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS

SALT LAKE CITY , April 27, 2023 /PRNewswire/ --  Sera Prognostics  Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report first quarter fiscal year 2023 financial results on Wednesday, May 10, 2023, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m.

Sera Prognostics Announces Conference Call and Webcast of First Quarter Fiscal Year 2023 Financial Results on May 10, 2023

Sera Prognostics, Inc. (SERA) Loses -13.03% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Sera Prognostics, Inc. (SERA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

News for Sera Prognostics Stock (SERA)